To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

One of the world’s biggest genetic databases comprises DNA data donated over the years by more than a million retired ...

Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune ...

Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition ...

Momentum in Johnson & Johnson’s cardiovascular business continues, while the company looks to regain its footing in the ...

The National Institutes of Health (NIH) has fired its chief operating officer amid a probe into whether his wife could have ...

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor ...

The artificial intelligence-powered spine surgery developer Carlsmed is showing some backbone as it kicks off its IPO, with ...

This story was updated at 5:30 p.m. ET to include comment from an investor call.   | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...